A novel series of deoxyvasicinone-tetrahydro-beta-carboline hybrids were synthesized and evaluated as acetylcholinesterase (AChE) and β-amyloid peptide (Aβ) aggregation inhibitors for the treatment of Alzheimer’s disease. The results revealed that the derivatives had multifunctional profiles, including AChE inhibition, Aβ_1-42 aggregation inhibition, and neuroprotective properties. Inspiringly, hybrids 8b and 8d displayed excellent inhibitory activities against hAChE (IC₅₀ = 0.93 and 1.08 nM, respectively) and Aβ₁₋₄₂ self-aggregation (IC₅₀ = 19.71 and 2.05 μM, respectively). In addition, 8b and 8d showed low cytotoxicity and good neuroprotective activity against Aβ₁₋₄₂-induced damage in SH-SY5Y cells.

一种新型系列deoxyvasicinone四氢的测试咔杂交的合成和评价为乙酰胆碱酯酶和β淀粉样肽（A β）聚集抑制剂为阿耳茨海默氏病的治疗。结果表明，该衍生物具有多功能个人资料，包括乙酰胆碱酯酶抑制，A β _1-42凝集抑制和神经保护性质。鼓舞地，杂种8B和8D显示针对优异的抑制活性ħ乙酰胆碱酯酶（IC ₅₀ 分别= 0.93和1.08纳米，）和A β _1-42自聚集（IC ₅₀ 分别为19.71和2.05μM）。另外，图8b和图8d显示出低细胞毒性和良好的神经保护活性对甲β _1-42在SH-SY5Y细胞诱导的损伤。